Modified, weekly dosing with docetaxel and cisplatin as first-line therapy in advanced non-small cell lung cancer
{{output}}
Background: Platinum-based combination chemotherapy regimens provide modest improvement in both survival and quality of life for patients with non-small cell lung cancers and docetaxel is the first agent approved for both first- ... ...
